Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rifampin (RIF) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

NCT02545439
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

NCT04118842
View directory record Official record
Conditions
Solid Tumors
Interventions
Savolitinib, Rifampicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

NCT02430545
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

NCT02197247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing, Pharmacokinetic sampling - rifampicin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 4, 2026, 12:34 AM EDT
Terminated Phase 3 Interventional Results available

Study of Rifampicin in Multiple System Atrophy

NCT01287221
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Rifampicin, placebo
Drug
Lead sponsor
Phillip Low
Other
Eligibility
30 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 4, 2026, 12:34 AM EDT
Terminated Phase 4 Interventional Results available

Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children

NCT00370149
View directory record Official record
Conditions
Infection Prevention
Interventions
Antibiotic-impregnated Catheters (M/R), Non-impregnated Catheters (C/S)
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 17 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

NCT02706535
View directory record Official record
Conditions
Drug Interactions, Neoplasms
Interventions
GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 4, 2026, 12:34 AM EDT
Recruiting Phase 2 Interventional

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

NCT03301038
View directory record Official record
Conditions
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Interventions
Rifampin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

NCT01947777
View directory record Official record
Conditions
Healthy
Interventions
IPI-145, Rifampin
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

NCT03755778
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

NCT01533870
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
NKTR-118, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

NCT02500667
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
N91115, Rifampin
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

NCT00351273
View directory record Official record
Conditions
Arthritis, Reactive, Reiter Disease
Interventions
Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Tampa, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 2 Interventional

Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis

NCT00043264
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rifampin, Azithromycin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 12:34 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

NCT05766267
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis Infection
Interventions
Rifabutin, Delamanid, Bedaquiline, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

NCT02729467
View directory record Official record
Conditions
Healthy
Interventions
JNJ-53718678, Itraconazole, Rifampicin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 12:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 4, 2026, 12:34 AM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802

NCT01940510
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5424802, rifampin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infections
Interventions
Rifabutin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 4, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

NCT01728363
View directory record Official record
Conditions
Systemic Infection
Interventions
Antibiotic
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
14 Days to 32 Weeks
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 4, 2026, 12:34 AM EDT